Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs

NCT ID: NCT00006316

Last Updated: 2008-08-01

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL

Brief Summary

The purpose of this study is to determine whether stopping preventive histoplasmosis medications in patients who are currently receiving effective anti-HIV drugs will place them at risk for getting histoplasmosis again.

Histoplasmosis is a serious opportunistic (AIDS-related) infection that responds well to antifungal medications. Before anti-HIV drugs, patients with histoplasmosis required lifelong antifungal therapy. Patients who take anti-HIV drugs for a long time may see an improvement in their immune system functions. Improved immune function may eliminate the need for long-term preventive treatment with antifungal agents. Doctors want to see if the improved immune functions allow preventive treatment for histoplasmosis to be stopped. (This study has been changed to include histoplasmosis treatment with drugs other than itraconazole.)

Detailed Description

Histoplasmosis is a serious opportunistic infection in persons with AIDS that demonstrates an excellent response to antifungal therapy. However, until the advent of highly active antiretroviral therapy (HAART), patients with histoplasmosis required lifelong suppressive antifungal therapy. It is thought that immune reconstitution as a result of HAART may diminish the need for chronic therapy. Histoplasmosis offers an opportunity to examine the concept of discontinuation of maintenance therapy as it is rapidly diagnosed and effectively treated with itraconazole [AS PER AMENDMENT 9/27/00: or other appropriate therapy for disseminated histoplasmosis] should relapse occur.

Patients discontinue antifungal maintenance therapy. Patients are seen for routine visits every 8 weeks and urine and serum specimens are collected for real time Histoplasma antigen testing and immunologic parameters. Patients with suspected recurrence, as determined by clinical or routine laboratory findings consistent with recurrent histoplasmosis, are reevaluated within 1 week of onset of these findings. Patients with suspected recurrence based on a serum or urine Histoplasma antigen rise of 2 units or more, in the absence of clinical or routine laboratory findings consistent with histoplasmosis, are reevaluated within 2 weeks. All patients with suspected recurrence have more frequent evaluations and additional laboratory tests. Those with negative studies resume bimonthly follow-up. All patients who develop proven (positive culture or positive fungal stain of tissues or body fluids) or probable relapse (clinical findings of relapse with an increase in antigen of 4.1 units or more, or no clinical findings but increases in antigen levels on repeated testing with the most recent antigen test demonstrating an increase in antigen of 4.1 units or more) or who experience persistent reduction of CD4 cell count to below 100/mm3 have antifungal induction therapy reinstituted. Patients remain on study for at least 12 months with regular follow-up/evaluations.

Conditions

HIV Infections; Histoplasmosis

Keywords

AIDS-Related Opportunistic Infections; Histoplasmosis; Antifungal Agents; Recurrence; Anti-HIV Agents

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are 13 years or older.
• Have consent of parent or guardian if under 18 years of age.
• Have HIV infection.
• Have 2 CD4 cell counts above 150 cells/mm3 (1 of which has been obtained within 6 months and the other within 30 days before entry). Note: The 2 CD4 counts used for eligibility must be from tests performed at least 1 week apart.
• Have received at least 1 year of treatment for histoplasmosis. (This study has been changed to include patients who have received histoplasmosis treatment with drugs other than itraconazole.)
• Are receiving treatment for histoplasmosis or have stopped treatment within 24 weeks of study entry.
• Have had histoplasmosis before but are free of any signs of histoplasmosis at entry into the study.
• Have a negative pregnancy test within 14 days of study entry.
• Have been on anti-HIV drugs for at least 24 successive weeks and have been on a stable anti-HIV drug combination for at least 8 weeks before entry.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have any recurrence of histoplasmosis within 4 weeks of study entry.
• Have received medications that affect the immune system including chemotherapy or corticosteroids within the last 2 months. (This study has been changed. Patients taking IL-2 are no longer excluded.)
• Have a systemic infection. Patients on stable preventive treatment for certain opportunistic (AIDS-related) infections for at least 3 months will be eligible.
• Require treatment for fungal infections with systemic antifungal medications.
• Have meningitis or brain or spinal cord damage thought to be caused by Histoplasma infection.

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Principal Investigators

Mitch Goldman

Role: STUDY_CHAIR

Judy Aberg

Role: STUDY_CHAIR

Locations

Univ of Southern California / LA County USC Med Ctr

Los Angeles, California, United States

University of California San Francisco

San Francisco, California, United States

Emory Univ

Atlanta, Georgia, United States

Cook County Hosp

Chicago, Illinois, United States

Indiana Univ Hosp

Indianapolis, Indiana, United States

Methodist Hosp of Indiana / Life Care Clinic

Indianapolis, Indiana, United States

Wishard Hosp

Indianapolis, Indiana, United States

Univ of Nebraska Med Ctr

Omaha, Nebraska, United States

Bellevue Hosp / New York Univ Med Ctr

New York, New York, United States

Univ of Cincinnati

Cincinnati, Ohio, United States

Ohio State Univ Hosp Clinic

Columbus, Ohio, United States

Julio Arroyo

West Columbia, South Carolina, United States

Univ of Texas, Southwestern Med Ctr of Dallas

Dallas, Texas, United States

Countries

United States

Other Identifiers

AACTG A5038

Identifier Type: -

Identifier Source: secondary_id

ACTG A5038

Identifier Type: -

Identifier Source: org_study_id